The Fox Chase Cancer Center is under new leadership since the last review and continues as one of the nation's few free standing comprehensive cancer centers. The Center's mission is "To prevail over cancer, marshaling excellence of heart and mind each day in the collaborative practice of bold scientific discovery, prevention strategies, and compassionate cancer care." Our vision is to be an acknowledged national leader in cancer research and medicine and a pre-eminent cancer center in the Philadelphia area. The new leadership in conjunction with advice from External Advisory Boards has consolidated the CCSG Research Programs from 11 to 5. These five Programs represent the core scientific strengths of the Fox Chase Cancer Center. At the last review 30 CCSG Shared Facilities and 2 support elements (Protocol Review and Monitoring System and Protocol Specific Research) were approved for funding with recommendations to consolidate facilities. This proposal requests partial support for 16 core facilities and 2 support elements. Developmental Funds are requested to strategically increase critical mass for these 5 research Programs over the CCSG funding cycle. A plan is presented to recruit 21 to 30 new and replacement investigators. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer-reviewed funding within 24 months of their appointment. Of that amount $5.1 million was garnered by investigators who were partially supported by Developmental Funds. Since the last submission, the Cancer Research Pavilion was completed as planned in 2010 and will provide much of the needed space for new investigator laboratories. The Leadership's vision includes a plan to increase team-based science via strategic keystone investments. These institutional investments are intended to expand the research portfolio of FCCC to include more "team-based" grants such as Program Project Grants and SPOREs. Several team-based science grant proposals will be submitted over the next few years as a direct result of these keystone Investments. To meet the demand presented by a future increase in principal investigators, the Center plans to leverage $8 million of ARRA funds with $5.1 million of institutional investment to construct a Comparative Medical Facility (CMR). Since the last review, FCCC has implemented a formal review mechanism to evaluate and prioritize its CCSG Shared Research Resources. As a result, of this evaluation process, the number of Shared Research Resources has been streamlined.

Public Health Relevance

NCI-designated Cancer Centers such as Fox Chase Cancer Center serve as major source of discovery of the nature of cancer, and development of more effective approaches to prevention, diagnosis and therapy.

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Austin, Steven R; Wong, Yu-Ning; Uzzo, Robert G et al. (2015) Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72
Bassi, Daniel E; Cenna, Jonathan; Zhang, Jirong et al. (2015) Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog 54:1122-31
Sherman, Kerry A; Miller, Suzanne M; Roussi, Pagona et al. (2015) Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema. Support Care Cancer 23:61-9
Eytan, Esther; Wang, Kexi; Miniowitz-Shemtov, Shirly et al. (2014) Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc Natl Acad Sci U S A 111:12019-24
Johnson, Matthew E; Handorf, Elizabeth A; Martin, Jeffrey M et al. (2014) Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer 120:3569-74
Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34
Silverman, Diana; Ruth, Karen; Sigurdson, Elin R et al. (2014) Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219:534-44
Gupta, Sapna; Melnyk, Stepan B; Kruger, Warren D (2014) Cystathionine *-synthase-deficient mice thrive on a low-methionine diet. FASEB J 28:781-90
Simhan, Jay; Smaldone, Marc C; Egleston, Brian L et al. (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114:216-20
Gowrishankar, Banumathy; Ibragimova, Ilsiya; Zhou, Yan et al. (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329-41

Showing the most recent 10 out of 475 publications